Senti Biosciences (SNTI) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

SNTI · Stock Price

USD 0.99-2.27 (-69.79%)

Market Cap: $30.5M

Historical price data

Market Cap: $30.5MPipeline: 2 drugsFounded: 2016Employees: 51-200HQ: South San Francisco, United States

Sector Ranking#74 in Cell & Gene Therapy #10 in Synthetic Biology

Overview

Senti Biosciences is leveraging its proprietary Gene Circuit platform to develop a new generation of intelligent cell therapies, primarily for oncology. The company's lead candidate, SENTI-202, is in a Phase 1 trial for acute myeloid leukemia (AML) and has shown positive preliminary efficacy. Senti's strategy combines advancing its wholly-owned pipeline with exploring platform applications in other modalities and diseases through partnerships.

OncologyHematology

Technology Platform

Proprietary synthetic biology platform for engineering 'Gene Circuits' into cell and gene therapies, enabling logic-gated functions for enhanced precision, control, and specificity.

Pipeline

2

2 drugs in pipeline

Drug	Indication	Stage	Watch
SN301A	Hepatocellular Carcinoma (HCC)	Phase 1
SENTI-202	AML/MDS	Phase 1

Opportunities

Senti's Gene Circuit platform addresses core limitations in cell therapy, offering a potential best-in-class solution for safety and specificity.

Successful clinical validation in AML could unlock significant value and enable expansion into the vast solid tumor market and other disease areas.

Risk Factors

The company faces high clinical development risk with its novel technology, severe financial risk as a pre-revenue firm with a low market cap, and intense competition in the advanced cell therapy space.

Competitive Landscape

Senti competes with other next-gen cell therapy firms (e.g., Autolus, Nkarta, Fate Therapeutics) and large pharma. Its key differentiator is a clinically-validated, modular synthetic biology platform designed specifically for programming complex logic into therapeutic cells.